Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure

Louis Cantor, Joni Hoop, L. Jay Katz, K. Flartey

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Brimonidine tartrate 0.2%, a selective alpha2-adrenergic receptor agonist, and betaxolol 0.25% suspension, a cardioselective beta1-adrenergic receptor antagonist, are used in the treatment of elevated intraocular pressure (IOP). Objective: This study compared the clinical success and quality-of-life impact of 4 weeks of treatment with brimonidine 0.2% BID compared with those of 4 weeks of treatment with betaxolol 0.25% suspension BID in patients with elevated IOP. Methods: This was a multisite, double-masked, comparative clinical trial in patients with glaucoma or ocular hypertension. Patients were randomly assigned to receive either brimonidine or betaxolol BID. Morning IOP was measured at baseline and at weeks 1 and 4 using Goldmann applanation. Efficacy was determined by reduction in IOP from baseline. Patients experiencing a ≥20% reduction in IOP were considered to have a successful IOP-lowering response. The Glaucoma Disability Index questionnaire was administered at week 4 to assess quality-of-life factors and the incidence of adverse events. Ophthalmic examinations were conducted at each visit. Results: One hundred fifty-nine patients were randomized to treatment and completed the study, 81 receiving brimonidine and 78 receiving betaxolol. The majority were white (77.4%) and female (61.6%), and had a diagnosis of open-angle glaucoma (56.0%). After 4 weeks of treatment, both brimonidine and betaxolol effectively lowered IOP from baseline (mean IOP reductions: brimonidine, 5.96 mm Hg; betaxolol, 5.07 mm Hg; P = NS). However, a significantly higher percentage of brimonidine patients (52/81 [64.2%]) than betaxolol patients (37/78 [47.4%]) had a ≥20% reduction in IOP (P = 0.033). No serious adverse events were reported with either study medication. On the quality-of-life assessments, more betaxolol patients reported hyperemia (P = 0.011), and the reported hyperemia was significantly more severe in betaxolol patients (P = 0.009). Conclusions: After 4 weeks of treatment, brimonidine 0.2% BID was clinically successful in significantly more patients and was better tolerated than 4 weeks of treatment with betaxolol 0.25% BID in this population.

Original languageEnglish
Pages (from-to)1032-1039
Number of pages8
JournalClinical Therapeutics
Volume23
Issue number7
DOIs
StatePublished - 2001

Fingerprint

Betaxolol
Intraocular Pressure
Suspensions
Quality of Life
Hyperemia
Glaucoma
Therapeutics
Brimonidine Tartrate
Ocular Hypertension
Adrenergic Agonists
Adrenergic Antagonists
Open Angle Glaucoma

Keywords

  • Betaxolol
  • Brimonidine
  • Glaucoma
  • Quality-of-life

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure. / Cantor, Louis; Hoop, Joni; Katz, L. Jay; Flartey, K.

In: Clinical Therapeutics, Vol. 23, No. 7, 2001, p. 1032-1039.

Research output: Contribution to journalArticle

@article{83e11c763c4f480cbe722c1305a01f88,
title = "Comparison of the clinical success and quality-of-life impact of brimonidine 0.2{\%} and betaxolol 0.25{\%} suspension in patients with elevated intraocular pressure",
abstract = "Background: Brimonidine tartrate 0.2{\%}, a selective alpha2-adrenergic receptor agonist, and betaxolol 0.25{\%} suspension, a cardioselective beta1-adrenergic receptor antagonist, are used in the treatment of elevated intraocular pressure (IOP). Objective: This study compared the clinical success and quality-of-life impact of 4 weeks of treatment with brimonidine 0.2{\%} BID compared with those of 4 weeks of treatment with betaxolol 0.25{\%} suspension BID in patients with elevated IOP. Methods: This was a multisite, double-masked, comparative clinical trial in patients with glaucoma or ocular hypertension. Patients were randomly assigned to receive either brimonidine or betaxolol BID. Morning IOP was measured at baseline and at weeks 1 and 4 using Goldmann applanation. Efficacy was determined by reduction in IOP from baseline. Patients experiencing a ≥20{\%} reduction in IOP were considered to have a successful IOP-lowering response. The Glaucoma Disability Index questionnaire was administered at week 4 to assess quality-of-life factors and the incidence of adverse events. Ophthalmic examinations were conducted at each visit. Results: One hundred fifty-nine patients were randomized to treatment and completed the study, 81 receiving brimonidine and 78 receiving betaxolol. The majority were white (77.4{\%}) and female (61.6{\%}), and had a diagnosis of open-angle glaucoma (56.0{\%}). After 4 weeks of treatment, both brimonidine and betaxolol effectively lowered IOP from baseline (mean IOP reductions: brimonidine, 5.96 mm Hg; betaxolol, 5.07 mm Hg; P = NS). However, a significantly higher percentage of brimonidine patients (52/81 [64.2{\%}]) than betaxolol patients (37/78 [47.4{\%}]) had a ≥20{\%} reduction in IOP (P = 0.033). No serious adverse events were reported with either study medication. On the quality-of-life assessments, more betaxolol patients reported hyperemia (P = 0.011), and the reported hyperemia was significantly more severe in betaxolol patients (P = 0.009). Conclusions: After 4 weeks of treatment, brimonidine 0.2{\%} BID was clinically successful in significantly more patients and was better tolerated than 4 weeks of treatment with betaxolol 0.25{\%} BID in this population.",
keywords = "Betaxolol, Brimonidine, Glaucoma, Quality-of-life",
author = "Louis Cantor and Joni Hoop and Katz, {L. Jay} and K. Flartey",
year = "2001",
doi = "10.1016/S0149-2918(01)80089-8",
language = "English",
volume = "23",
pages = "1032--1039",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "7",

}

TY - JOUR

T1 - Comparison of the clinical success and quality-of-life impact of brimonidine 0.2% and betaxolol 0.25% suspension in patients with elevated intraocular pressure

AU - Cantor, Louis

AU - Hoop, Joni

AU - Katz, L. Jay

AU - Flartey, K.

PY - 2001

Y1 - 2001

N2 - Background: Brimonidine tartrate 0.2%, a selective alpha2-adrenergic receptor agonist, and betaxolol 0.25% suspension, a cardioselective beta1-adrenergic receptor antagonist, are used in the treatment of elevated intraocular pressure (IOP). Objective: This study compared the clinical success and quality-of-life impact of 4 weeks of treatment with brimonidine 0.2% BID compared with those of 4 weeks of treatment with betaxolol 0.25% suspension BID in patients with elevated IOP. Methods: This was a multisite, double-masked, comparative clinical trial in patients with glaucoma or ocular hypertension. Patients were randomly assigned to receive either brimonidine or betaxolol BID. Morning IOP was measured at baseline and at weeks 1 and 4 using Goldmann applanation. Efficacy was determined by reduction in IOP from baseline. Patients experiencing a ≥20% reduction in IOP were considered to have a successful IOP-lowering response. The Glaucoma Disability Index questionnaire was administered at week 4 to assess quality-of-life factors and the incidence of adverse events. Ophthalmic examinations were conducted at each visit. Results: One hundred fifty-nine patients were randomized to treatment and completed the study, 81 receiving brimonidine and 78 receiving betaxolol. The majority were white (77.4%) and female (61.6%), and had a diagnosis of open-angle glaucoma (56.0%). After 4 weeks of treatment, both brimonidine and betaxolol effectively lowered IOP from baseline (mean IOP reductions: brimonidine, 5.96 mm Hg; betaxolol, 5.07 mm Hg; P = NS). However, a significantly higher percentage of brimonidine patients (52/81 [64.2%]) than betaxolol patients (37/78 [47.4%]) had a ≥20% reduction in IOP (P = 0.033). No serious adverse events were reported with either study medication. On the quality-of-life assessments, more betaxolol patients reported hyperemia (P = 0.011), and the reported hyperemia was significantly more severe in betaxolol patients (P = 0.009). Conclusions: After 4 weeks of treatment, brimonidine 0.2% BID was clinically successful in significantly more patients and was better tolerated than 4 weeks of treatment with betaxolol 0.25% BID in this population.

AB - Background: Brimonidine tartrate 0.2%, a selective alpha2-adrenergic receptor agonist, and betaxolol 0.25% suspension, a cardioselective beta1-adrenergic receptor antagonist, are used in the treatment of elevated intraocular pressure (IOP). Objective: This study compared the clinical success and quality-of-life impact of 4 weeks of treatment with brimonidine 0.2% BID compared with those of 4 weeks of treatment with betaxolol 0.25% suspension BID in patients with elevated IOP. Methods: This was a multisite, double-masked, comparative clinical trial in patients with glaucoma or ocular hypertension. Patients were randomly assigned to receive either brimonidine or betaxolol BID. Morning IOP was measured at baseline and at weeks 1 and 4 using Goldmann applanation. Efficacy was determined by reduction in IOP from baseline. Patients experiencing a ≥20% reduction in IOP were considered to have a successful IOP-lowering response. The Glaucoma Disability Index questionnaire was administered at week 4 to assess quality-of-life factors and the incidence of adverse events. Ophthalmic examinations were conducted at each visit. Results: One hundred fifty-nine patients were randomized to treatment and completed the study, 81 receiving brimonidine and 78 receiving betaxolol. The majority were white (77.4%) and female (61.6%), and had a diagnosis of open-angle glaucoma (56.0%). After 4 weeks of treatment, both brimonidine and betaxolol effectively lowered IOP from baseline (mean IOP reductions: brimonidine, 5.96 mm Hg; betaxolol, 5.07 mm Hg; P = NS). However, a significantly higher percentage of brimonidine patients (52/81 [64.2%]) than betaxolol patients (37/78 [47.4%]) had a ≥20% reduction in IOP (P = 0.033). No serious adverse events were reported with either study medication. On the quality-of-life assessments, more betaxolol patients reported hyperemia (P = 0.011), and the reported hyperemia was significantly more severe in betaxolol patients (P = 0.009). Conclusions: After 4 weeks of treatment, brimonidine 0.2% BID was clinically successful in significantly more patients and was better tolerated than 4 weeks of treatment with betaxolol 0.25% BID in this population.

KW - Betaxolol

KW - Brimonidine

KW - Glaucoma

KW - Quality-of-life

UR - http://www.scopus.com/inward/record.url?scp=0034904822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034904822&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(01)80089-8

DO - 10.1016/S0149-2918(01)80089-8

M3 - Article

C2 - 11519768

AN - SCOPUS:0034904822

VL - 23

SP - 1032

EP - 1039

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 7

ER -